Zanubrutinib Shows Worth Against Standard CLL Drugs
Patients with chronic lymphocytic leukemia could soon be offered a novel treatment option after trial data showed zanubrutinib improves outcomes against standard therapies.
Source: medscape.com
Page 4 - Peter Hillmen News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Peter Hillmen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Peter Hillmen Today - Breaking & Trending Today
BeiGene Announces European Med - GuruFocus.com
GuruFocus Article or News written by Business Wire and the topic is about:
Source: gurufocus.com
BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma
BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma - read this article along with other careers information, tips and advice on BioSpace
Source: biospace.com
Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLL
Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease
Source: medpagetoday.com
European Hematology Association - ALPINE Study Reveals Superior Safety and Efficacy of Zanubrutinib Compared with Ibrutinib
THE HAGUE, Netherlands, June 11, 2021 /PRNewswire/ -- Inhibition of B-cell receptor signaling via Bruton tyrosine kinase (BTK) has been a breakthrough for the treatment of chronic lymphocytic
Source: finanznachrichten.de